{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:52:13Z","timestamp":1790776333916,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.coi.2021.03.008","type":"journal-article","created":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T19:19:41Z","timestamp":1618773581000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"special_numbering":"C","title":["Ebola virus disease: current vaccine solutions"],"prefix":"10.1016","volume":"71","author":[{"given":"Oyewale","family":"Tomori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Olatunji","family":"Kolawole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2021.03.008_bib0005","series-title":"Resources: Introduction to Ebola Disease: Managing Infectious Hazards","author":"World Health Organization (WHO)","year":"2020"},{"key":"10.1016\/j.coi.2021.03.008_bib0010","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0297","article-title":"The Ebola outbreak, 2013-2016: old lessons for new epidemics","volume":"372","author":"Coltart","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.coi.2021.03.008_sbref0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/erv.10.152","article-title":"Progress in filovirus vaccine development: evaluating the potential for clinical use","volume":"10","author":"Falzarano","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2021.03.008_bib0020","series-title":"WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries","author":"WHO","year":"2019"},{"key":"10.1016\/j.coi.2021.03.008_bib0025","unstructured":"\u201cErvebo\u201d U.S. Food and Drug Administration FDA 19 December 2019, Retrieved 12 February 2021. https:\/\/www.fda.gov\/vaccines-blood-biologics\/ervebo."},{"key":"10.1016\/j.coi.2021.03.008_bib0030","unstructured":"\u201cErvebo\u201d EPAR. European Medicine Agency EMA 12 December 2019, Retrieved 12 February 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ervebo."},{"key":"10.1016\/j.coi.2021.03.008_sbref0035","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.coi.2021.03.008_sbref0040","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2021.03.008_sbref0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/JVI.01515-07","article-title":"Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus Type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice","volume":"82","author":"Cooper","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2021.03.008_bib0050","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.vaccine.2011.12.085","article-title":"Evaluation of attenuated VSVs with mutated M or\/and G proteins as vaccine vectors","volume":"30","author":"Fang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2021.03.008_bib0055","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2021.03.008_bib0060","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.1016\/j.vaccine.2008.09.082","article-title":"Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses","volume":"26","author":"Geisbert","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2021.03.008_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000225","article-title":"Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates","volume":"4","author":"Geisbert","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coi.2021.03.008_bib0070","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2021.03.008_bib0075","doi-asserted-by":"crossref","DOI":"10.4172\/2157-2526.S1-004","article-title":"Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections","volume":"1","author":"Marzi","year":"2011","journal-title":"J Bioterr Biodef"},{"key":"10.1016\/j.coi.2021.03.008_sbref0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.coi.2021.03.008_bib0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2021.03.008_bib0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.15585\/mmwr.su6503a14","article-title":"Implementing an Ebola Vaccine Study - Sierra Leone","volume":"65","author":"Widdowson","year":"2016","journal-title":"MMWR Suppl"},{"key":"10.1016\/j.coi.2021.03.008_sbref0095","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2021.03.008_sbref0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230406","article-title":"Impact of prophylactic vaccination strategies on Ebola virus transmission: a modeling analysis","volume":"15","author":"Potluri","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2021.03.008_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7001a1","article-title":"Use of Ebola vaccine: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"70","author":"Choi","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.coi.2021.03.008_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12910-017-0201-1","article-title":"Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic","volume":"18","author":"Alirol","year":"2017","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.coi.2021.03.008_sbref0115","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3934\/publichealth.2019.4.502","article-title":"Recurrent Ebolavirus disease in the democratic republic of Congo: update and challenges","volume":"6","author":"Inungu","year":"2020","journal-title":"AIMS Public Health"},{"key":"10.1016\/j.coi.2021.03.008_bib0120","series-title":"National Center for Emerging and Zoonotic Infectious Diseases","article-title":"Viral Hemorrhagic Fevers (VHFs): Ebola (Ebola Virus Disease)","author":"Centers for Diseases Control and Prevention (CDC)","year":"2020"},{"key":"10.1016\/j.coi.2021.03.008_sbref0125","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/14760584.2018.1546582","article-title":"Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?","volume":"17","author":"Huttner","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coi.2021.03.008_sbref0130","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3390\/microorganisms8101473","article-title":"To B or not to B: mechanisms of protection conferred by rVSV-EBOV-GP and the roles of innate and adaptive immunity","volume":"8","author":"Pinski","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.coi.2021.03.008_bib0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/d41586-019-03490-8","article-title":"Make Ebola a thing of the past: first vaccine against deadly virus approved","volume":"575","author":"Ewen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coi.2021.03.008_bib0140","series-title":"Ebola Vaccine Frequently Asked Questions","author":"World Health Organization (WHO)","year":"2020"},{"key":"10.1016\/j.coi.2021.03.008_bib0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40475-019-00195-w","article-title":"Maternal and infant death and the rVSV-ZEBOV vaccine through three recent Ebola virus epidemics-West Africa, DRC \u00c9quateur and DRC Kivu: 4 years of excluding pregnant and lactating women and their infants from immunization","volume":"6","author":"Schwartz","year":"2019","journal-title":"Curr Trop Med Rep"},{"key":"10.1016\/j.coi.2021.03.008_bib0150","unstructured":"World Health Organization (WHO) Resources: Overview of candidate Ebola vaccines. https:\/\/www.who.int\/immunization\/sage\/meetings\/2019\/october\/6_Ebola_Candidate_Vaccines_19-09-19.pdf."},{"key":"10.1016\/j.coi.2021.03.008_bib0155","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","article-title":"Ebola virus disease","volume":"393","author":"McElroy","year":"2019","journal-title":"Lancet"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791521000285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791521000285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:45:52Z","timestamp":1760604352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791521000285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":31,"alternative-id":["S0952791521000285"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2021.03.008","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ebola virus disease: current vaccine solutions","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2021.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}